Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
The University of Kansas Cancer Center, Westwood, Kansas, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
251 Airforce & VA General Hospital, Athens, Greece
424 General Military Hospital, Thessaloniki, Greece
Aksaray University Training and Research Hospital, Aksaray, Turkey
Department of Endrocinology and Internal Medicine, Aarhus, Denmark
Department of rheumatology, Dhaka, Shahbag, Bangladesh
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Caritas Medical Centre, Sham Shui Po, Hong Kong
Queen Mary Hospital, Hong Kong, Hong Kong
United Christian Hospital, Kwun Tong, Hong Kong
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.